Biomedical Advanced Research and Development Authority
Biomedical Advanced Research and Development Authority
Explore linked clinical trials.27 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) | Influenza A | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07128615 | |
| A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Phase 2 | 2026-10-09 | NCT06672055 | |
| A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Infections, Male Urogenital Diseases, Urogenital Diseases, urinary system disorder, urinary tract infection | Recruiting | Phase 1 | 2026-09-30 | NCT07645235 | |
| Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA) | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, influenza, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Not stated | 2026-09-30 | NCT06160128 | |
| Observational, Non-interventional Biomarker and Endotyping Study | Lung Injury, acute lung injury, lung disorder, respiratory system disorder | Recruiting | Not stated | 2026-09-28 | NCT07675265 | |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health | Filoviridae infectious disease, Infections, Marburg hemorrhagic fever, Mononegavirales infectious disease, RNA Virus Infections, monkey disease, non-human animal disease, non-human primate disease, viral hemorrhagic fever, viral infectious disease | Recruiting | Phase 1 | 2026-09-23 | NCT07425821 | |
| A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy Adults | Healthy Participants | Recruiting | Phase 1 | 2026-09-22 | NCT07035769 | |
| A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health | Ebola hemorrhagic fever, Filoviridae infectious disease, Infections, Mononegavirales infectious disease, RNA Virus Infections, viral hemorrhagic fever, viral infectious disease | Recruiting | Phase 1 | 2026-09-21 | NCT07565090 | |
| Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children | Accidental Injuries, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Shock, Hemorrhagic, injury | Recruiting | Phase 3 | 2026-09-17 | NCT06070350 | |
| A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. | Bacterial Infections and Mycoses, Infections, fungal infectious disease | Recruiting | Phase 3 | 2026-09-14 | NCT06925321 | |
| A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. | Bacterial Infections and Mycoses, Fungemia, Infections, Inflammation, Invasive Fungal Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome, Torulopsis, candidemia, candidiasis, candidiasis, invasive, fungal infectious disease | Recruiting | Phase 3 | 2026-09-14 | NCT05421858 | |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis | acute pyelonephritis | Active, not recruiting | Phase 2 | 2026-09-10 | NCT06672978 | |
| A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults | Filoviridae infectious disease, Infections, Marburg hemorrhagic fever, Mononegavirales infectious disease, RNA Virus Infections, monkey disease, non-human animal disease, non-human primate disease, viral hemorrhagic fever, viral infectious disease | Active, not recruiting | Phase 2 | 2026-09-10 | NCT06620003 | |
| Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS) | Infections, Respiration Disorders, adult acute respiratory distress syndrome, lung disorder, respiratory failure, respiratory system disorder | Recruiting | Phase 2 | 2026-09-10 | NCT05947955 | |
| A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections | Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Surgical Wound Infection, Wound Infection | Recruiting | Phase 1 | 2026-08-17 | NCT07379684 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06703073 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06701682 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06701669 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06701656 | |
| Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination | Drug-Drug Interaction (DDI); FDC; Healthy Volunteer; Pharmacokinetics; Safety | Recruiting | Phase 1 | 2026-07-09 | NCT06733675 | |
| Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns | burn, injury | Active, not recruiting | Not applicable | 2026-02-24 | NCT04090424 | |
| A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults | Ebola Sudan Virus Disease | Active, not recruiting | Phase 2 | 2026-02-10 | NCT06803342 | |
| Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario | Bacillaceae infectious disease, Bacterial Infections and Mycoses, Infections, anthrax infection, bacterial infectious disease, gram-positive bacterial infections | Not yet recruiting | Phase 4 | 2026-02-06 | NCT02177721 | |
| Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults | Respiration Disorders, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Not yet recruiting | Phase 2 | 2026-02-02 | NCT06564207 | |
| Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Not applicable | 2025-10-02 | NCT06744660 |